HomeCompareCIHHF vs PFE

CIHHF vs PFE: Dividend Comparison 2026

CIHHF yields 6.72% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIHHF wins by $237.6K in total portfolio value
10 years
CIHHF
CIHHF
● Live price
6.72%
Share price
$6.07
Annual div
$0.41
5Y div CAGR
36.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$287.2K
Annual income
$124,685.95
Full CIHHF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CIHHF vs PFE

📍 CIHHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIHHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIHHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIHHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIHHF
Annual income on $10K today (after 15% tax)
$571.38/yr
After 10yr DRIP, annual income (after tax)
$105,983.06/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CIHHF beats the other by $83,663.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIHHF + PFE for your $10,000?

CIHHF: 50%PFE: 50%
100% PFE50/50100% CIHHF
Portfolio after 10yr
$168.4K
Annual income
$75,472.34/yr
Blended yield
44.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CIHHF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.3
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIHHF buys
0
PFE buys
0
No recent congressional trades found for CIHHF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIHHFPFE
Forward yield6.72%6.13%
Annual dividend / share$0.41$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR36.5%13.2%
Portfolio after 10y$287.2K$49.6K
Annual income after 10y$124,685.95$26,258.71
Total dividends collected$246.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: CIHHF vs PFE ($10,000, DRIP)

YearCIHHF PortfolioCIHHF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,618$917.56$9,153$693.39+$2.5KCIHHF
2$13,791$1,359.88$8,593$849.25+$5.2KCIHHF
3$16,815$2,059.30$8,336$1,066.78+$8.5KCIHHF
4$21,196$3,203.23$8,437$1,384.80+$12.8KCIHHF
5$27,830$5,150.83$9,013$1,875.40+$18.8KCIHHF
6$38,406$8,627.72$10,306$2,680.72+$28.1KCIHHF
7$56,283$15,188.96$12,820$4,101.38+$43.5KCIHHF
8$88,619$28,396.06$17,673$6,826.70+$70.9KCIHHF
9$151,859$57,036.79$27,543$12,591.86+$124.3KCIHHF
10$287,175$124,685.95$49,560$26,258.71+$237.6KCIHHF

CIHHF vs PFE: Complete Analysis 2026

CIHHFStock

China Merchants Bank Co., Ltd., together with its subsidiaries, provides various banking products and services. It operates through Wholesale Finance Business, Retail Finance Business, and Other Business segments. The company offers current, demand, time, call, savings, notice, and renminbi accounts. Its loan products include personal commercial real estate, consumption, housing, and car loans; loans to finance for studying abroad; micro-business loans; mortgage loans for equipment; joint guarantee, special guarantee, and housing mortgage loan; bank acceptance, discount, liquid capital, and fixed asset loans; and loans for vessels. The company also offers credit cards; insurance products; open-ended funds; discount and guarantees for commercial bills, redemption of commercial bills, and guaranteed discount for commercial acceptance bills; and financial consultation, debt financing underwriting, merger and acquisition financing, and equity financing and enterprise listing services. In addition, it provides forfeiting and risk participation, escrow, cross-border RMB clearing, and interbank services; and risk and financial management, cross-border RMB and oversea financing, international factoring and settlement, and trade finance services. Further, the company offers financial leasing and guarantee, investment and wealth management, forex option and gold trading, forex express trading, international, offshore and private banking, custody, pension, and electronic banking services. As of December 31, 2021, it operated 143 branches; 1,770 sub-branches; one branch-level operation center; 2,812 self-service centers; 6,592 self-service machines; one representative office; 14,746 visual counters in Mainland China. The company also operates in Hong Kong, New York, London, Singapore, Luxembourg, Sydney, and Taipei. China Merchants Bank Co., Ltd. was founded in 1987 and is headquartered in Shenzhen, China.

Full CIHHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CIHHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIHHF vs SCHDCIHHF vs JEPICIHHF vs OCIHHF vs KOCIHHF vs MAINCIHHF vs JNJCIHHF vs MRKCIHHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.